Insulet Corporation (PODD)

NASDAQ · Health Care · market cap 10.04B

Share price

$141.55

At the last nightly close

Intrinsic value

$92.38

A single conservative estimate.

Margin of safety

-34.7%

($92.38 − $141.55) ÷ $141.55

EV / EBIT

379.9

On the median operating profit of 15 fiscal years through 2025.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.

Key metrics

Price / earnings26.6
Price / book6.9
EV / EBITDA16.5
FCF / EV-0.3%
Return on equity+26.0%
Return on assets+9.7%
Debt / equity0.67
Gross margin+71.1%

Market position

52-week high$346.36
52-week low$131.96
From 52-week high-59.1%
RSI (14)46.3
200-day moving average$196.67

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY2.71B473.8M247.1M3.51349.9M
2024-FY2.07B308.9M418.3M5.97296.2M
2023-FY1.70B220.1M206.3M2.9636.5M
2022-FY1.31B37.6M4.6M0.07-38.3M
2021-FY1.10B126.0M16.8M0.24-180.0M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedNovember 5, 2026
Consensus EPS estimate1.59

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on PODD.

Run the board on PODD

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.